Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Sponsor: Hebei Medical University Fourth Hospital
Summary
The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
Official title: To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-08-01
Completion Date
2027-06-01
Last Updated
2025-06-26
Healthy Volunteers
No
Conditions
Interventions
Camrelizumab+chemotherapy
Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy: AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles. Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles.
hypofractionated radiotherapy
Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),
Locations (1)
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China